卡佩西塔诱导的严重耐火性腹用甲基普雷尼索隆治疗:一个病例报告
Tanmay Jain1, Itish Patnaik1, Sweety Gupta2
1Gastroenterology and Hepatology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND.
化疗诱导的腹 (CID) 是capecitabine治疗的常见副作用. 这项案例研究表明,甲基普雷迪尼索隆有效地控制了严重的,耐治疗的CID,这表明了潜在的新治疗选择.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 化疗诱导的腹 (CID) 是一种常见的,通常是剂量限制性毒性.
- 开佩奇他经常与CID相关,大多数病例是轻微的.
- 目前的指导方针建议在严重的CID管理中使用洛佩拉米德和奥克特里奥提德.
更多相关视频
06:21Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
03:25Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
Published on: December 27, 2024
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
